Intranasal delivery of neural stem/progenitor cells: a noninvasive passage to target intracerebral glioma.
Standard
Intranasal delivery of neural stem/progenitor cells: a noninvasive passage to target intracerebral glioma. / Reitz, Matthias; Demestre, Maria; Sedlacik, Jan; Meissner, Hildegard; Fiehler, Jens; Kim, Seung U; Westphal, Manfred; Schmidt, Nils-Ole.
In: STEM CELL TRANSL MED, Vol. 1, No. 12, 12, 2012, p. 866-873.Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Intranasal delivery of neural stem/progenitor cells: a noninvasive passage to target intracerebral glioma.
AU - Reitz, Matthias
AU - Demestre, Maria
AU - Sedlacik, Jan
AU - Meissner, Hildegard
AU - Fiehler, Jens
AU - Kim, Seung U
AU - Westphal, Manfred
AU - Schmidt, Nils-Ole
PY - 2012
Y1 - 2012
N2 - Stem cell-based therapies for neurological disorders, including brain tumors, advance continuously toward clinical trials. Optimized cell delivery to the central nervous system remains a challenge since direct intracerebral injection is an invasive method with low transplantation efficiency. We investigated the feasibility of intranasal administration of neural stem/progenitor cells (NSPCs) as an alternative, noninvasive, and direct passage for the delivery of stem cells to target malignant gliomas. Tumor-targeting and migratory pathways of murine and human NSPCs were investigated by intravital magnetic resonance imaging and in histological time course analyses in the intracerebral U87, NCE-G55T2, and syngenic Gl261 glioblastoma models. Intranasally administered NSPCs displayed a rapid, targeted tumor tropism with significant numbers of NSPCs accumulating specifically at the intracerebral glioma site within 6 hours after intranasal delivery. Histological time series analysis revealed that NSPCs migrated within the first 24 hours mainly via olfactory pathways but also by systemic distribution via the microvasculature of the nasal mucosa. Intranasal application of NSPCs leads to a rapid, targeted migration of cells toward intracerebral gliomas. The directional distribution of cells accumulating intra- and peritumorally makes the intranasal delivery of NSPCs a promising noninvasive and convenient alternative delivery method for the treatment of malignant gliomas with the possibility of multiple dosing regimens.
AB - Stem cell-based therapies for neurological disorders, including brain tumors, advance continuously toward clinical trials. Optimized cell delivery to the central nervous system remains a challenge since direct intracerebral injection is an invasive method with low transplantation efficiency. We investigated the feasibility of intranasal administration of neural stem/progenitor cells (NSPCs) as an alternative, noninvasive, and direct passage for the delivery of stem cells to target malignant gliomas. Tumor-targeting and migratory pathways of murine and human NSPCs were investigated by intravital magnetic resonance imaging and in histological time course analyses in the intracerebral U87, NCE-G55T2, and syngenic Gl261 glioblastoma models. Intranasally administered NSPCs displayed a rapid, targeted tumor tropism with significant numbers of NSPCs accumulating specifically at the intracerebral glioma site within 6 hours after intranasal delivery. Histological time series analysis revealed that NSPCs migrated within the first 24 hours mainly via olfactory pathways but also by systemic distribution via the microvasculature of the nasal mucosa. Intranasal application of NSPCs leads to a rapid, targeted migration of cells toward intracerebral gliomas. The directional distribution of cells accumulating intra- and peritumorally makes the intranasal delivery of NSPCs a promising noninvasive and convenient alternative delivery method for the treatment of malignant gliomas with the possibility of multiple dosing regimens.
KW - Animals
KW - Humans
KW - Cells, Cultured
KW - Disease Models, Animal
KW - Mice
KW - Mice, Inbred C57BL
KW - Cell Movement
KW - Magnetic Resonance Imaging
KW - Cell Line, Tumor
KW - Neoplasm Transplantation
KW - Transplantation, Heterologous
KW - Administration, Intranasal/methods
KW - Brain Neoplasms/pathology/therapy
KW - Fibroblasts/cytology
KW - Frontal Lobe/cytology
KW - Glioblastoma/pathology/therapy
KW - Neural Stem Cells/cytology/transplantation
KW - Parietal Lobe/cytology
KW - Stem Cell Transplantation/methods
KW - Animals
KW - Humans
KW - Cells, Cultured
KW - Disease Models, Animal
KW - Mice
KW - Mice, Inbred C57BL
KW - Cell Movement
KW - Magnetic Resonance Imaging
KW - Cell Line, Tumor
KW - Neoplasm Transplantation
KW - Transplantation, Heterologous
KW - Administration, Intranasal/methods
KW - Brain Neoplasms/pathology/therapy
KW - Fibroblasts/cytology
KW - Frontal Lobe/cytology
KW - Glioblastoma/pathology/therapy
KW - Neural Stem Cells/cytology/transplantation
KW - Parietal Lobe/cytology
KW - Stem Cell Transplantation/methods
U2 - 10.5966/sctm.2012-0045
DO - 10.5966/sctm.2012-0045
M3 - SCORING: Journal article
VL - 1
SP - 866
EP - 873
JO - STEM CELL TRANSL MED
JF - STEM CELL TRANSL MED
SN - 2157-6564
IS - 12
M1 - 12
ER -
